NCT05069272招募中不适用
A Randomized, Double-blinded, Vehicle Controlled, Monocentric Study to Evaluate the Efficacy and Tolerance of Synergistic Combination of Bakuchiol and Ethyl Linoleate on Mild to Moderate Acne Vulgaris
Ratan K. Chaudhuri2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2021年9月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Facial lesions
研究概览
简要总结
Subjects will be assigned to a active cream or vehicle to compare the cosmetic effects. This will take place over a 12 week period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy female volunteers, aged 18 years or older;
- •with mild to moderate acne;
- •Subjects must have between 10-100 non-inflammatory lesions and 10-50 inflammatory lesions but no more than 2 nodular lesions and no cysts on their face.
- •If applicable, users of estrogens/birth control pills must have been on the treatment regimen for at least 3 months and be willing to continue use for study duration;
- •Females of child-bearing potential (FCBP): A female is considered not to be of childbearing potential if she is post-menopausal with at least 12 consecutive months of amenorrhea or has undergone surgical sterilization. While on the study, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:
- •Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR
- •Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
- •Willing to follow study instructions and available to attend the study visits;
- •Willing to provide written informed consent and sign photography release
排除标准
- •Female subjects: Self-reported pregnant or breast feeding, or planning to become pregnant during the course of the study;
- •Known allergy or hypersensitivity to acne treatment products;
- •Current skin disease of any type in the test area (e.g. eczema, psoriasis, rosacea, seborrheic dermatitis, vitiligo, etc.), or under the treatment of a doctor for any skin condition;
- •Have any cystic acne, acne conglobate, acne fulminans, or secondary acne (chloracne or drug-induced acne) in the test area;
- •Any conditions on the test site that would interfere with evaluations (i.e. tattoos, scars, open cuts, sunburn, piercings, excessive hair, etc.);
- •Use of topical treatments such as OTC (over the counter) acne medication topical anti-inflammatory medications, salicylic acid, corticosteroids, antibiotics, anti-bacterials, peroxide-containing products, or retinoids within 2 weeks of baseline;
- •Use of depigmenting medications such as hydroquinone during the 14 days prior to the study start; Insulin dependent diabetes;
- •Concurrent medication that might affect the response to the test articles including routine use of anti-inflammatory medications, anti-histamines, and steroids;
- •History of Crohn's disease, or clinically significant enteritis (regional enteritis, ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis);
- •Microdermabrasion or laser treatment in the test area within six months of the study;
- •Medical condition which, in the opinion of the Investigator, would compromise the safety of the subject or confound study results;
- •Use of systemic antibiotics, corticosteroids, antimalarials or oral dapsone within 4 weeks of baseline;
- •Use of other anti-acne medications, including isotretinoin or spironolactone, within 6 months of baseline;
- •Participation on an investigational drug study within 4 months of the baseline visit.
结局指标
主要结局
Facial lesions
时间窗: From baseline to week 12
Percent reductions in facial lesion counts for inflammatory and noninflammatory
IGA Score
时间窗: From baseline to week 12
IGA score of zero (clear) or one (almost clear)
次要结局
- Post inflammatory hyperpigmentation(From baseline to week 2, 4, 8 & 12)
- Total lesion count(From baseline to week 12)
- Inflammatory and non-inflammatory leisons(From baseline to week 2, 4, 8 & 12)
- IGA score(From baseline to week 2, 4, 8 & 12)
研究者
Ratan K. Chaudhuri
President
Sytheon Ltd.
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy SubjectsHealthyNCT01567683Moberg Pharma AB
已完成
4 期
Pediatric Subjects With Tinea CorporisTinea CorporisNCT02227290Merz North America, Inc.230
已完成
2 期
Safety and Efficacy Study in Subjects With Seborrheic DermatitisSeborrheic DermatitisNCT01703793Medicis Global Service Corporation240
已完成
不适用
A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.Head LicePediculosis CapitisNCT03617926Oystershell NV70
终止
不适用
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and CellsOpen Angle GlaucomaNCT00478036University of Colorado, Denver31